News About: Pharm. Industry
KFDA approves Galvus, new oral treatment for type 2 diabetesNovartis Korea says the Korea Food and Drug Administration (KFDA) has approved Galvus (vildagliptin), a new oral treatment for type 2 diabetes.
As a member of the new class o...
|
Big 3 medicinal patch makers eye pharmacy market
Stimulated by the government's plan that medicinal patch preparations would not covered by the national insurance fund sooner or later, three leading drug makers Pacific Pharm, Jeil Pharm and SK Chemicals plan to ex...
Yuhan's 10 medicines break 10-billion mark in 2007 sales
Yuhan Corporation's ten flagship products exceeded 10-billion sales last year, propelled by strong demand in related sectors.
Of these items, Yuhan's new drug Revanex (revaprazan) surpassed a 10 billion mark in...
Domestic and foreign pharmaceutical firms to improve mutual collaborations
Domestic pharmaceutical firms are seeking to cement their mutual collaboration with foreign pharmaceutical firms by holding a regular meeting every two months, according to the Korea Pharmaceutical Manufacturers Assoc...
Drug makers seek more tax exemptions for R&D spending
The Korea Pharmaceutical Manufacturers Association (KPMA) will seek to expand tax exemptions for corporate investment in research and development (R&D) as part of efforts to stimulate pharmaceutical companies' R&D spe...
Trius, U.S. Dong-A' partner, initiates Phase I trial for oxazolidinone antibacterial drug
Dong-A Pharm announced on January 7 that its U.S. partner Trius Therapeutics initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-p...
Price of Baraclude to be reduced
The Ministry of Health and Welfare says health insurance price of BMS Korea's Baraclude (entecavir) will be reduced based on the guideline of the Korean Association for the Study of the Liver and clinical period, whil...
Validation outsourcing market heats up
Domestic outsourcing market for validation is likely to gain momentum as the Korea Food and Drug Administration plans to implement more advanced GMP (good manufacturing practice) for new drugs and related validation p...
AZK is likely to break W200 billion in annual sales
Boosted by increase in sales of Crestor (rosuvastatin) and Atacand as strategic items, AstraZeneca Korea saw its sales in 2007 exceed 200 billion won, up 16 percent from last year's 172.7 billion won. The combined sal...
Green Cross to open Green Cell Center
Green Cross Corporation (GCC) says it has opened a cGMP based green cell center at Yongin, Kyunggi Province to produce cell therapeutics.
Its Mokam institute set up "LifeLine", a umbilical code blood bank, in 2003 ...
